XOMA Corporation (XOMA)

NASDAQ: XOMA · IEX Real-Time Price · USD
20.85
-0.39 (-1.84%)
Jan 27, 2023, 4:00 PM EST - Market closed
-1.84%
Market Cap 238.75M
Revenue (ttm) 40.49M
Net Income (ttm) 9.79M
Shares Out 11.45M
EPS (ttm) 0.85
PE Ratio 24.53
Forward PE 30.49
Dividend n/a
Ex-Dividend Date n/a
Volume 9,654
Open 20.97
Previous Close 21.24
Day's Range 20.53 - 21.26
52-Week Range 15.68 - 32.09
Beta 0.93
Analysts Buy
Price Target 63.75 (+205.76%)
Earnings Date Mar 14, 2023

About XOMA

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 a... [Read more]

Industry Biotechnology
Sector Healthcare
CEO James Neal
Employees 12
Stock Exchange NASDAQ
Ticker Symbol XOMA
Full Company Profile

Financial Performance

In 2021, XOMA's revenue was $38.16 million, an increase of 29.86% compared to the previous year's $29.39 million. Earnings were $7.79 million, a decrease of -11.44%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for XOMA stock is "Buy." The 12-month stock price forecast is $63.75, which is an increase of 205.76% from the latest price.

Price Target
$63.75
(205.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, th...

3 weeks ago - GlobeNewsWire

New Executive Leadership Team Appointed to Accelerate XOMA's Differentiated Royalty Monetization Strategy

Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer

3 weeks ago - GlobeNewsWire

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to ho...

1 month ago - GlobeNewsWire

XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay

2 months ago - GlobeNewsWire

Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -140% and 95.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events

Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).  First five...

3 months ago - GlobeNewsWire

XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...

5 months ago - GlobeNewsWire

Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of -381.82% and 88.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

The completion of Regeneron's acquisition of Checkmate Pharmaceuticals resulted in a $5 million milestone payment to Kuros, $2.5 million of which was paid to XOMA in July.

6 months ago - GlobeNewsWire

Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment

Ad-hoc announcement pursuant to Article 53 of the SIX listing rules

Other symbols: REGN
8 months ago - GlobeNewsWire

XOMA to Present at H.C. Wainwright Global Investment Conference

EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improving...

9 months ago - GlobeNewsWire

Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates

Xoma (XOMA) delivered earnings and revenue surprises of 5.88% and 12.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022.  Rezolute has announced its ...

9 months ago - GlobeNewsWire

XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference

EMERYVILLE, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...

11 months ago - GlobeNewsWire

XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

Earned $35 million milestone payment as NIS793 entered Phase 3 clinical study  in metastatic pancreatic cancer

11 months ago - GlobeNewsWire

XOMA to Present at the 42nd Annual Cowen Health Care Conference

EMERYVILLE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvi...

11 months ago - GlobeNewsWire

XOMA to Present at Aegis Capital Corp Investor Conference

EMERYVILLE, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvin...

1 year ago - GlobeNewsWire

XOMA to Present at Upcoming Investor Conferences

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator playing a distinctive role in helping companies achieve their goal of improvin...

1 year ago - GlobeNewsWire

XOMA Announces Evolution of Company Leadership and Succession Planning

Chief Executive Officer Jim Neal appointed as Chairman; Former Chairman W. Denman Van Ness to remain Lead Independent Director

1 year ago - GlobeNewsWire

XOMA Earns $35 Million Milestone Payment as Anti-TGFβ Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer

EMERYVILLE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced today NIS793, an anti-TGFβ monoclonal antibody licensed from the Company, has advanced to the Phase 3 de...

1 year ago - GlobeNewsWire

XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events

Added eight assets to its portfolio of potential milestone and royalty assets in 2021

1 year ago - GlobeNewsWire

Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know

Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength?

Xoma (XOMA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

1 year ago - Zacks Investment Research

XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

EMERYVILLE, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA)'s Chief Executive Officer, Jim Neal, will present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Confere...

1 year ago - GlobeNewsWire

XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference

EMERYVILLE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Inv...

1 year ago - GlobeNewsWire